MML Investors Services LLC lifted its position in Boston Scientific Co. (NYSE:BSX) by 11.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,044 shares of the medical equipment provider’s stock after acquiring an additional 2,196 shares during the quarter. MML Investors Services LLC’s holdings in Boston Scientific were worth $744,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of the company. We Are One Seven LLC acquired a new position in shares of Boston Scientific during the 4th quarter valued at $27,000. Ipswich Investment Management Co. Inc. purchased a new position in shares of Boston Scientific during the fourth quarter valued at $28,000. Athena Capital Advisors LLC purchased a new position in shares of Boston Scientific during the fourth quarter valued at $28,000. CWM LLC grew its holdings in shares of Boston Scientific by 54.3% during the fourth quarter. CWM LLC now owns 1,020 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 359 shares in the last quarter. Finally, West Oak Capital LLC boosted its position in Boston Scientific by 40.0% during the fourth quarter. West Oak Capital LLC now owns 1,050 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 300 shares during the last quarter. Institutional investors own 91.70% of the company’s stock.
Shares of BSX traded up $0.20 on Friday, hitting $35.11. The company’s stock had a trading volume of 10,280,978 shares, compared to its average volume of 8,091,470. The company has a market capitalization of $48.82 billion, a P/E ratio of 23.88, a PEG ratio of 2.06 and a beta of 0.87. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.76 and a quick ratio of 0.54. Boston Scientific Co. has a fifty-two week low of $27.91 and a fifty-two week high of $41.00.
In other Boston Scientific news, SVP Maulik Nanavaty sold 3,039 shares of the company’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $40.32, for a total transaction of $122,532.48. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP David A. Pierce sold 5,000 shares of the stock in a transaction on Friday, February 1st. The shares were sold at an average price of $38.15, for a total value of $190,750.00. Following the completion of the transaction, the executive vice president now directly owns 29,201 shares in the company, valued at approximately $1,114,018.15. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 342,352 shares of company stock worth $13,701,434. Company insiders own 0.66% of the company’s stock.
BSX has been the subject of a number of research reports. Zacks Investment Research cut Boston Scientific from a “hold” rating to a “sell” rating in a research report on Monday, December 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $43.00 price target on shares of Boston Scientific in a research report on Tuesday, January 8th. Guggenheim reaffirmed a “buy” rating and issued a $48.00 price target on shares of Boston Scientific in a research report on Friday, February 8th. SunTrust Banks reaffirmed a “buy” rating and issued a $47.00 price target on shares of Boston Scientific in a research report on Friday, February 8th. Finally, Canaccord Genuity reissued a “buy” rating and set a $45.00 price objective on shares of Boston Scientific in a research report on Monday, February 11th. Three investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $40.72.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Featured Article: Put Option Volume
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.